Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives $14.80 Average PT from Analysts

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have been assigned an average recommendation of “Reduce” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $14.80.

IART has been the subject of a number of research reports. Wells Fargo & Company lowered their price objective on Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating for the company in a research report on Friday, February 27th. Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th.

Institutional Investors Weigh In On Integra LifeSciences

A number of institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in shares of Integra LifeSciences during the fourth quarter worth $124,000. Invesco Ltd. lifted its holdings in Integra LifeSciences by 0.9% during the fourth quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock worth $43,754,000 after acquiring an additional 31,931 shares in the last quarter. Corient Private Wealth LLC bought a new position in Integra LifeSciences during the fourth quarter worth about $189,000. State of Tennessee Department of Treasury grew its stake in Integra LifeSciences by 7.9% in the fourth quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after acquiring an additional 1,964 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of Integra LifeSciences by 2.4% in the fourth quarter. Wellington Management Group LLP now owns 1,353,467 shares of the life sciences company’s stock worth $16,810,000 after acquiring an additional 32,192 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

IART opened at $10.39 on Monday. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. The stock has a market capitalization of $809.80 million, a P/E ratio of -1.54 and a beta of 1.02. The company’s 50 day simple moving average is $11.83 and its 200-day simple moving average is $13.12. Integra LifeSciences has a one year low of $9.96 and a one year high of $24.36.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.04. The firm had revenue of $434.93 million for the quarter, compared to the consensus estimate of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The business’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.97 EPS. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Sell-side analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.